MarketCap
Facebook
X
Telegram
QIAGEN N.V. EBITDA | QGEN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 660 M | 301 M | 615 M | 740 M | 845 M | 591 M | 205 M | 473 M | 370 M | 138 M | 214 M | 198 M | 98.8 M | 206 M | 126 M | 331 M | 229 M | 188 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 845 M | 98.8 M | 363 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
OPKO Health
OPK
|
-25.8 M | $ 1.63 | 1.23 % | $ 1.22 B |  USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 7.3 | -0.06 % | $ 2.62 B |  Irlanda |
 |
T2 Biosystems
TTOO
|
-48.8 M | - | -39.35 % | $ 313 K | USA |
 |
Bioventus
BVS
|
101 M | $ 14.75 | -1.44 % | $ 983 M | USA |
 |
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Precipio
PRPO
|
43 K | $ 19.5 | -2.55 % | $ 31.3 M | USA |
 |
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
RadNet
RDNT
|
214 M | $ 69.9 | -0.63 % | $ 5.26 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.55 B | $ 26.55 | -1.28 % | $ 25.2 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-66.8 M | $ 7.46 | -0.67 % | $ 311 M | USA |
 |
Sotera Health Company
SHC
|
94.9 M | $ 18.35 | 1.35 % | $ 5.21 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.8 B | $ 684.39 | 1.57 % | $ 258 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-111 M | $ 145.39 | 3.91 % | $ 8.7 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 65.75 | 0.76 % | $ 3.07 B | USA |
 |
VolitionRx Limited
VNRX
|
-20.8 M | $ 0.18 | 0.83 % | $ 22.6 M |  Singapore |
 |
Waters Corporation
WAT
|
359 M | $ 456.36 | 0.39 % | $ 27.2 B | USA |
 |
Exagen
XGN
|
-12 M | $ 7.44 | 2.34 % | $ 160 M | USA |
 |
Quotient Limited
QTNT
|
-96.6 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
3.05 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
47.2 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
650 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K |  Israel |
 |
Castle Biosciences
CSTL
|
-2.04 M | $ 32.84 | -0.73 % | $ 952 M | USA |
 |
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
-29.2 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
-793 K | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
70.9 M | - | - | $ 1.49 B | USA |
 |
CareDx, Inc
CDNA
|
-15.8 M | $ 69.1 | -0.17 % | $ 3.68 B | USA |
 |
Co-Diagnostics
CODX
|
-49.1 M | $ 0.55 | 0.4 % | $ 732 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 242.85 | 0.4 % | $ 27 B | USA |
 |
Danaher Corporation
DHR
|
5.44 B | $ 232.83 | 1.01 % | $ 166 B | USA |
 |
DexCom
DXCM
|
1.16 B | $ 77.9 | -0.05 % | $ 30.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
826 M | $ 183.8 | -0.79 % | $ 14.4 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.51 B | $ 568.9 | 1.52 % | $ 45.8 B | USA |
 |
Illumina
ILMN
|
1.08 B | $ 268.6 | -0.3 % | $ 41.6 B | USA |
 |
IQVIA Holdings
IQV
|
3.33 B | $ 273.81 | -1.99 % | $ 47.1 B | USA |
 |
Medpace Holdings
MEDP
|
562 M | $ 676.93 | 1.16 % | $ 19.5 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M | Britain |
 |
Brainsway Ltd.
BWAY
|
1.39 M | $ 11.18 | -0.61 % | $ 380 M | Israel |
 |
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.94 | -1.84 % | $ 95.4 K | USA |
|
Biodesix
BDSX
|
-22.2 M | $ 21.5 | 1.51 % | $ 162 M | USA |
 |
BioNano Genomics
BNGO
|
-23.8 M | $ 1.15 | 1.77 % | $ 6.26 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
-36.3 M | $ 3.31 | -12.2 % | $ 13.2 M | Israel |
 |
Personalis
PSNL
|
-78 M | $ 15.89 | 0.22 % | $ 1.42 B | USA |